The Breast Cancer Stem Cells Traits and Drug Resistance

被引:71
作者
Zheng, Qinghui [1 ]
Zhang, Mengdi [2 ,3 ]
Zhou, Fangfang [4 ,5 ]
Zhang, Long [2 ,3 ]
Meng, Xuli [1 ]
机构
[1] Zhejiang Prov Peoples Hosp, Dept Breast Surg, Hangzhou, Peoples R China
[2] Zhejiang Univ, MOE Lab Biosyst Homeostasis & Protect, Life Sci Inst, Hangzhou, Peoples R China
[3] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Life Sci Inst, Hangzhou, Peoples R China
[4] Soochow Univ, Inst Biol, Suzhou, Peoples R China
[5] Soochow Univ, Inst Med Sci, Suzhou, Peoples R China
关键词
breast cancer stem cells; drug resistance; clinical therapy; surface markers; breast cancer stem cell signaling pathways; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INITIATING CELLS; HEDGEHOG SIGNALING PATHWAY; ENDOCRINE THERAPY RESISTANCE; SMALL-MOLECULE INHIBITOR; FACTOR-I RECEPTOR; ESTROGEN-RECEPTOR; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE; MULTIDRUG-RESISTANCE;
D O I
10.3389/fphar.2020.599965
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug resistance is a major challenge in breast cancer (BC) treatment at present. Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the BC drugs resistance, causing relapse and metastasis in BC patients. Thus, BCSCs elimination could reverse drug resistance and improve drug efficacy to benefit BC patients. Consequently, mastering the knowledge on the proliferation, resistance mechanisms, and separation of BCSCs in BC therapy is extremely helpful for BCSCs-targeted therapeutic strategies. Herein, we summarize the principal BCSCs surface markers and signaling pathways, and list the BCSCs-related drug resistance mechanisms in chemotherapy (CT), endocrine therapy (ET), and targeted therapy (TT), and display therapeutic strategies for targeting BCSCs to reverse drug resistance in BC. Even more importantly, more attention should be paid to studies on BCSC-targeted strategies to overcome the drug resistant dilemma of clinical therapies in the future.
引用
收藏
页数:24
相关论文
共 300 条
  • [1] DNA damage response and resistance of cancer stem cells
    Abad, Etna
    Graifer, Dmitry
    Lyakhovich, Alex
    [J]. CANCER LETTERS, 2020, 474 : 106 - 117
  • [2] The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas
    Adams, Brian D.
    Parsons, Christine
    Slack, Frank J.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (06) : 737 - 753
  • [3] Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
    Aktas, Bahriye
    Tewes, Mitra
    Fehm, Tanja
    Hauch, Siegfried
    Kimmig, Rainer
    Kasimir-Bauer, Sabine
    [J]. BREAST CANCER RESEARCH, 2009, 11 (04)
  • [4] Prospective identification of tumorigenic breast cancer cells
    Al-Hajj, M
    Wicha, MS
    Benito-Hernandez, A
    Morrison, SJ
    Clarke, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 3983 - 3988
  • [5] Breast cancer prognosis by combinatorial analysis of gene expression data
    Alexe G.
    Alexe S.
    Axelrod D.E.
    Bonates T.O.
    Lozina I.I.
    Reiss M.
    Hammer P.L.
    [J]. Breast Cancer Research, 8 (4)
  • [6] High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer
    Alves, Carla L.
    Elias, Daniel
    Lyng, Maria
    Bak, Martin
    Kirkegaard, Tove
    Lykkesfeldt, Anne E.
    Ditzel, Henrik J.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5514 - 5526
  • [7] Implications of stemness-related signaling pathways in breast cancer response to therapy
    Angeloni, Valentina
    Tiberio, Paola
    Appierto, Valentina
    Daidone, Maria Grazia
    [J]. SEMINARS IN CANCER BIOLOGY, 2015, 31 : 43 - 51
  • [8] Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1α
    Arnason, Terra
    Harkness, Troy
    [J]. CANCERS, 2015, 7 (04) : 2063 - 2082
  • [9] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
    Arpino, Grazia
    Wiechmann, Lisa
    Osborne, C. Kent
    Schiff, Rachel
    [J]. ENDOCRINE REVIEWS, 2008, 29 (02) : 217 - 233
  • [10] Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
    Baccelli, Irene
    Schneeweiss, Andreas
    Riethdorf, Sabine
    Stenzinger, Albrecht
    Schillert, Anja
    Vogel, Vanessa
    Klein, Corinna
    Saini, Massimo
    Baeuerle, Tobias
    Wallwiener, Markus
    Holland-Letz, Tim
    Hoefner, Thomas
    Sprick, Martin
    Scharpff, Martina
    Marme, Frederik
    Sinn, Hans Peter
    Pantel, Klaus
    Weichert, Wilko
    Trumpp, Andreas
    [J]. NATURE BIOTECHNOLOGY, 2013, 31 (06) : 539 - U143